Feraoun Yanis, Maisonnasse Pauline, Le Grand Roger, Beignon Anne-Sophie
Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Département IDMIT (Infectious Disease Models and Innovative Therapies), UMR 1184, Université Paris-Saclay, Unité Inserm 1184, CEA, 18 route du Panorama, 92265 Fontenay-aux-Roses, France.
Med Sci (Paris). 2021 Aug-Sep;37(8-9):759-772. doi: 10.1051/medsci/2021094. Epub 2021 Jun 3.
A vaccine is required to effectively control the COVID-19 pandemic in the mid and long term. The development of vaccines against SARS-CoV-2 was initiated as soon as the genetic sequence of the virus was published, and has evolved at an unprecedented speed, with a first clinical trial launched in March 2020. One year later, more than a dozen of vaccines based on different concepts, with some having been evaluated only in clinical trials so far, are authorized under emergency procedures. Here, we review these vaccines, compare their properties and discuss the challenges they face, including the emergence of viral variants of concern.
从长远来看,需要一种疫苗来有效控制新冠疫情。自新冠病毒的基因序列公布后,针对该病毒的疫苗研发工作便立即启动,并以前所未有的速度推进,2020年3月开展了首次临床试验。一年后,有十几种基于不同理念的疫苗通过紧急程序获得授权,其中一些疫苗目前仅在临床试验中进行了评估。在此,我们对这些疫苗进行综述,比较它们的特性,并讨论它们面临的挑战,包括令人担忧的病毒变种的出现。